Abstract
Background: Heparin-induced thrombocytopenia (HIT) is a rare but serious complication of heparin therapy. The diagnosis of HIT is difficult because its signs are non-specific and the heparin-platelet factor 4 (PF4) antibody test used to confirm the diagnosis is imprecise. Drugs used to treat HIT are costly and may carry an increased risk of bleeding.
Objective: To evaluate the cost effectiveness, from a societal perspective, of four treatment approaches for patients with suspected HIT within a US critical care setting.
Methods: A decision-tree was constructed for the management of a hypothetical cohort of critical care patients with possible evidence of HIT.
The management strategies were: (i) no antibody testing, continue heparin (No Test and Wait); (ii) antibody testing, continue heparin while test results pending (Test and Wait); (iii) antibody testing and switch to a direct thrombin inhibitor (DTI) while test results pending (Test and Switch); and (iv) no antibody testing but switch to a DTI (No Test and Switch). We used argatroban as the DTI in our analysis.
The outcomes were direct medical costs ($US; 2004 values), QALYs and incremental cost-effectiveness ratios (ICERs).
Results: Assuming an HIT prevalence of 3%, relative to less costly strategies, ordering an antibody test and switching patients to argatroban if the result was positive (Test and Wait) had an ICER of $US163 396/QALY. Pre-emptive switching to argatroban without antibody testing (No Test and Switch) was the most effective strategy but had an ICER of >$US1 million/QALY relative to the Test and Switch option. These results were highly sensitive to HIT prevalence among patients presenting with thrombocytopenia.
Assuming a willingness to pay of $US50 000 per QALY, the Test and Wait strategy became cost effective when the prior probability of HIT was 8%. At a prior probability of 12%, Test and Switch was cost effective, and at probabilities of HIT in the 60–75% range, No Test and Switch was cost effective. In two-way analysis, the probability of developing a thrombotic event was a key driver of treatment choice at specific HIT probabilities.
Conclusions: Testing for HIT in all typical critical care patients with thrombocytopenia is unlikely to represent a cost-effective management strategy. With increasing probability of HIT, strategies that include testing and a more rapid switch to a DTI appear more desirable. Accurate clinical judgment of the prior probability of HIT has a critical influence on the cost-effective management of HIT.
Similar content being viewed by others
References
Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121 (4): 535–555
Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005; 127 (2): 35S–45S
Verma AK, Levine M, Shalansky S J, et al. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003; 23 (6): 745–753
Crowther MA, Cook DJ, Meade MO, et al. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care 2005; 20 (4): 348–353
Warkentin TE, Greinacher A. Heparin-induced thrombo-cytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl.): 311S–371S
Call JT, Deliargyris EN, Sane DC. Direct thrombin inhibitors in the treatment of immune-mediated heparin-induced thrombocytopenia. Semin Thromb Hemost 2004; 30 (3): 297–314
Thomson Corporation. Drug Topics Red book. Montvale (NJ): Thomson PDR, 2004: v
Gold MR, Siegel JE Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332 (20): 1330–1335
Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163 (20): 2518–2524
Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96 (3): 846–851
Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban antico-agulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103 (14): 1838–1843
Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163 (15): 1849–1856
Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101 (5): 502–507
Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106 (6): 629–635
Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005; 94 (1): 132–135
Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enox-aparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA 2004; 292 (1): 89–96
Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95 (3): 315–328
Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100 (15): 1593–1601
Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 1995; 108 (4 Suppl.): 276S–290S
Juergens CP, Semsarian C, Keech AC, et al. Hemorrhagic complications of intravenous heparin use. Am J Cardiol 1997; 80 (2): 150–154
Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a “standard care” nomogram: a randomized controlled trial. Ann Intern Med 1993; 11 (9): 874–881
Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous mromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83 (1): 14–19
Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl.): 287S–310S
Moledina M, Chakir M, Gandhi PJ. A synopsis of the clinical uses of argatroban. J Thromb Haemost 2001; 12 (2): 141–149
Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002; 126 (11): 1415–1423
Menzin J, Colditz GA, Regan MM, et al. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995; 155 (7): 757–764
Devlin JW, Petitta A, Shepard AD, et al. Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma. Pharmacotherapy 1998; 18 (6): 1335–1342
Gould MK, Dembitzer AD, Sanders GD, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann Intern Med 1999; 130 (10): 789–799
O’Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003; 25 (3): 1017–1038
O’Brien JA, Caro JJ. Direct medical cost of managing deep vein thrombosis according to the occurrence of complications. Pharmacoeconomics 2002; 20 (9): 603–615
Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med 1997; 157 (3): 298–303
Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13 (2): 89–102
Hunink MG, Wong JB, Donaldson MC, et al. Revascularization for femoropopliteal disease. A decision and cost-effectiveness analysis. JAMA 1995; 274 (2): 165–171
Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002; 22 (4): 340–349
Sculpher M, Michaels J, McKenna M, et al. A cost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions. Int J Technol Assess Health Care 1996; 12 (1): 104–125
Eckman MH, Greenfield S, Mac key WC, et al. Foot infections in diabetic patients: decision and cost-effectiveness analyses. JAMA 1995; 273 (9): 712–720
Brothers TE, Cox MH, Robison JG, et al. Prospective decision analysis modeling indicates that clinical decisions in vascular surgery often fail to maximize patient expected utility. J Surg Res 2004; 120 (2): 278–287
CEA Registry. Catalog of Preference Scores. Vol 2004 [online]. Available from URL: http://www.tufts-nemc.org/cearegistry/data/default.asp [Accessed 2007 Sep 24]
Tengs TO, Yu M, Luistro E. Health-related quality of life after stroke a comprehensive review. Stroke 2001; 32 (4): 964–972
Arias E. United States life tables, 2002. National Vital Statistics Reports; vol 53 no 6. Hyattsville (MD): National Center for Health Statistics, 2004
Center on the Evaluation of Value and Risk in Health. The cost-effectiveness analysis registry. Boston: Tufts-New England Medical Center, ICRHPS [online]. Available from URL: http://www.tufts-nemc.org/icrhps/resprog/cevr/ [Accessed 2007 Oct 25]
Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146 (4): 473–481
Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002; 22 (5): 417–430
Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology (Am See Hematol Educ Program) 2003: 497–519
Jang IK, Brown DF, Giugliano RP, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol 1999; 33 (7): 1879–1885
Hirahara T, Kubo N, Ohmura N, et al. Prospective randomized study of argatroban versus heparin anticoagulation therapy after percutaneous coronary intervention for acute myocardial infarction [in Japanese]. J Cardiol 2004; 44 (2): 47–52
Fanikos J, Stapinski C, Koo S, et al. Medication errors associated with anticoagulant therapy in the hospital. Am J Cardiol 2004; 94 (4): 532–535
Lube now N, Eichler P, Greinacher A. Results of a large drug monitoring program confirms the safety and efficacy of Refludan (lepirudin) in patients with immune-mediated heparin-induced thrombocytopenia (HIT) [abstract]. Blood 2002; 100: 502a
Lube now N, Eichler P, Lietz T, et al. Lepirudin in patients with heparin-induced thrombocytopenia: results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005; 3 (11): 2428–2436
Warkentin TW. Thrombotic end point for assessing argatroban therapy for heparin-induced thrombocytopenia: learning from secondary analyses of prospective studies. Chest 2006; 129 (6): 1396–1398
Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354 (4): 353–365
Parody R, Oliver A, Souto JC, et al. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica 2003; 88 (11): ECR32
Acknowledgements
No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study. The authors had full access to the data and take responsibility for its integrity. All authors have read and agreed to the manuscript as written.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Patrick, A.R., Winkelmayer, W.C., Avorn, J. et al. Strategies for the Management of Suspected Heparin-Induced Thrombocytopenia. Pharmacoeconomics 25, 949–961 (2007). https://doi.org/10.2165/00019053-200725110-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200725110-00005